Takeda/Affymax Recall ESA Omontys After Patient Deaths
This article was originally published in PharmAsia News
Executive Summary
Takeda had soured on the drug in Japan as it shifted away from renal therapies, but the drug’s future is now in doubt.
You may also be interested in...
Fresenius News Not All Bad For Affymax’s Omontys
Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.